# 1 Title: Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a

# 2 proclivity for immune-privileged organ-tropism

4	Authors: Axel Künstner <sup>1,2</sup> *, Vera von Kopylow <sup>1,3,4</sup> *, Philipp Lohneis <sup>4</sup> *, Matthias
5	Kümmel <sup>1,3,4</sup> , Hanno M. Witte <sup>1,3,5</sup> , Lorenz Bastian <sup>1,6</sup> , Veronica Bernard <sup>4</sup> , Stephanie Stölting <sup>4</sup> ,
6	Kathrin Kusch <sup>4</sup> , Manuela Krokowski <sup>4</sup> , Nikolas von Bubnoff <sup>1,3</sup> , Konrad Steinestel <sup>7</sup> , Annette
7	Arndt <sup>7</sup> , Hartmut Merz <sup>4</sup> , Hauke Busch <sup>1,2**</sup> , Alfred C. Feller <sup>4**</sup> , Niklas Gebauer <sup>1,3**</sup>
8	
9	Affiliations:
10	<sup>1</sup> University Cancer Center Schleswig-Holstein, University Hospital of Schleswig-Holstein,
11	Campus Lübeck, 23538 Lübeck, Germany
12	<sup>2</sup> Medical Systems Biology Group, University of Lübeck, Ratzeburger Allee 160, 23538
13	Lübeck, Germany
14	<sup>3</sup> Department of Hematology and Oncology, University Hospital of Schleswig-Holstein,
15	Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
16	<sup>4</sup> Hämatopathologie Lübeck, Reference Centre for Lymph Node Pathology and
17	Hematopathology, Maria-Goeppert-Straße 9a, 23562 Lübeck, Germany.
18	<sup>5</sup> Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Oberer
19	Eselsberg 40, 89081 Ulm
20	<sup>6</sup> Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein,
21	Kiel, Germany.
22	<sup>7</sup> Department of Pathology, Federal Armed Forces Hospital Ulm, Oberer Eselsberg 40, 89081
23	Ulm
24	

- 25
- 26

- 27 Running Title: Molecular landscape in primary renal DLBCL
- 28 Key Words: PR-DLBCL, molecular landscape, immune-privileged site, MHC Class I and II
- 29 Word Count (Abstract): 200
- 30 Word Count (Text): 3.782
- 31 References: 57
- 32 Figures: 6
- 33 Supplementary Tables: 8
- 34 Supplemental Figures: 4
- 35 Supplementary References: 9
- 36 Competing Interests: Niklas Gebauer received travel support from Beigene, Janssen, and
- 37 Roche as well as honoraria from Roche, Takeda, Janssen, Menarini Stemline, and
- 38 AstraZeneca.
- 39
- 40 \*These authors contributed equally to this manuscript.
- 41 \*\*Shared senior authorship
- 42 Date of submission: 28.06.2024
- 43
- 44 Corresponding Author:
- 45 PD Dr. med. Niklas Gebauer
- 46 Department of Hematology and Oncology
- 47 UKSH Campus Luebeck
- 48 Ratzenburger Allee 160
- 49 23538 Luebeck
- 50 Email: <u>Niklas.Gebauer@uksh.de</u>

### 52 Abstract:

53 Primary renal manifestations of diffuse large B-cell lymphoma (PR-DLBCL) represent an 54 exceptionally rare variant of the most common type of non-Hodgkin lymphoma (NHL). 55 Insights into PR-DLBCL pathogenesis have been limited to small case series and 56 methodologically limited approaches. The mechanisms driving lymphomagenesis within an 57 organ lacking an intrinsic lymphatic niche and its proclivity for dissemination to immune-58 privileged sites, including testes and central nervous system, remain poorly understood. To 59 decode the genetic and transcriptional framework of PR-DLBCL, we utilized whole exome 60 sequencing, array-based somatic copy number alterations analysis, and RNA sequencing. 61 Hereby we characterize the most extensive cohort of PR-DLBCL published, comprising 34 62 samples from 30 patients. Despite significant mutational heterogeneity with a broad 63 distribution among molecular clusters, we observed a strong unifying enrichment in 64 deleterious MHC class I and II aberrations and loss of CDKN2A at a frequency similar to 65 primary large B-cell lymphoma of immune privileged sites (IP-LBCL) alongside significant 66 transcriptional deregulation of interferon signaling and MYC targets in MHC class I-deficient 67 cases.

68 Our integrative assessment of PR-DLBCL biology expands the molecular understanding of 69 this rare variant including similarities with IP-LBCL as an intriguing explanation for its 70 clinical behavior and tropism. Our observations may inform future risk-adapted therapeutic 71 approaches.

72

#### 73 **Introduction:**

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and accounts for 30 – 40% of newly diagnosed lymphomas <sup>1</sup>. Extranodal manifestations in both the adrenal glands and the kidneys constitute long-standing risk factors for developing simultaneous or secondary CNS manifestations <sup>2</sup>. Secondary renal

78 involvement is recurrently observed in advanced-stage non-Hodgkin lymphoma (NHL), 79 whereas primary renal (PR-) NHL manifestations are notably less frequent, leading to skepticism regarding the existence of primary renal lymphoma for an extended period <sup>2-6</sup>. 80 81 Population-based datasets suggest an age-adjusted incidence of 0.035/100,000 with an 82 increasing tendency, a median age of approximately 70 years at diagnosis, a male 83 predominance, and mostly unilateral tumors. Among PR-NHL, DLBCL appears to be the 84 most common histology followed by marginal zone (MZL) and follicular lymphoma (FL)<sup>7,8</sup>. 85 Clinical differentiation of PR-NHL from other renal malignancies including renal cell 86 carcinoma poses a long-standing challenge, which led to a substantial number of PR-NHL patients undergoing curatively intended resection <sup>9</sup>. In recent years, the introduction of FDG-87 88 PET-CTs into routine clinical practice has enabled a more reliable characterization, 89 particularly in patients with more aggressive PR-NHL<sup>10</sup>.

90 Insufficient characterization of pathogenetic mechanisms in indolent PR-DLBCL derives 91 from limited data, primarily comprised of small case series and a lack of in-depth molecular 92 characterization of patients and samples <sup>11</sup>. Molecular drivers of lymphomas originating from 93 organs lacking an intrinsic lymphatic niche, such as the kidney, remain widely elusive apart from individual case studies <sup>12</sup>. To elucidate the genetic and transcriptional landscape and 94 95 drivers of PR-DLBCL, we conducted a comprehensive investigation employing whole exome 96 sequencing (WES), array-based analysis of somatic copy number alterations (SCNA), and 97 RNA sequencing (RNA-seq) to unravel both molecular properties of this rare entity as well as 98 the cellular composition of its tumor microenvironment (TME).

99

### 100 Materials and methods

#### 101 Case selection and clinicopathological assessment

102 For this retrospective analysis, we reviewed our institutional archive for cases of103 histologically confirmed primary renal DLBCL between January 2001 and December 2021.

104 Only such cases without concurrent non-renal lymphoma manifestations at diagnosis were 105 included in the study, which led to a large subset of samples obtained by complete renal 106 resection under the suspicion of non-metastatic renal cell carcinoma (22/34 samples; 65%). 107 The study was approved by the ethics committee of the University of Lübeck (reference-no 108 18-356) and conducted per the declaration of Helsinki. Patients provided written informed 109 consent regarding routine diagnostic and academic assessment, including genomic studies. 110 Histopathological work-up was performed as described and diagnosis was confirmed following the 5<sup>th</sup> edition WHO classification of hematopoietic and lymphoid tumors and the 111 112 ICC criteria and yielded 34 cases of PR-DLBCL for which sufficient formalin-fixed paraffinembedded (FFPE) tissue samples were available for subsequent molecular analysis <sup>1, 13, 14</sup>. 113

114

#### **Delineation of the molecular composition of the study cohort**

116 Extraction of nucleic acids, WES and RNA-seq alongside detection of Somatic Copy Number

117 Alterations employing the OncoScan CNV array (ThermoFisher was performed as described,

and Raw fastq files have been added to the European Genome-phenome archive (EGA) under

119 the previous accession number EGA5000000386<sup>13, 15</sup>. OncoScan Array data has been

deposited in Gene Expression Omnibus (GEO) under accession number GSE270422.

121

### 122 Whole exome data processing and variant calling

123 The raw sequencing data in FASTQ format was processed using the NFORE workflow 124 (NEXTFLOW v23.10.1) SAREK (v3.3.2) for variant calling against the GRCh38 reference 125 genome <sup>16, 17</sup>. Initially, reads were trimmed for adapter sequences and quality using FASTP 126 (v0.23.4), followed by alignment with BWA MEM2 (v2.2.1) <sup>18, 19</sup>. Subsequent steps included 127 mate-pair information correction, removal of PCR duplicates, and base quality recalibration 128 utilizing PICARD TOOLS, GATK (v4.4.0.0), and dbSNP v146 <sup>20, 21</sup>. Finally, variant calling was 129 executed in tumor-only mode using MUTECT2 with GNOMAD (r2.1.1) as the reference for

22, 23 130 known germline variants Variants left aligned (GATK were 131 LEFTALIGNANDTRIMVARIANTS) and only variants with a PASS filter flag were kept for 132 variant annotation using VARIANT EFFECT PREDICTOR (VEP v111, GRCh38; adding CADD v1.6, dbNSFP v4.1a, and GNOMAD r3.0 as additional annotations)<sup>24-26</sup>. Next, annotations 133 134 were converted into MAF format using VCF2MAF (V1.6.21) 135 (DOI:10.5281/ZENODO.593251); coverage was extracted directly from the vcf INFO field.

136 Potential FFPE artifacts in the variant data were identified using two approaches. First, strand 137 orientation biases (mutations just found on one strand, F1R2 or F2R1) were detected by SOBDETECTOR (v1.0.4) and potential artifacts were removed <sup>27</sup>. Next, a classifier detecting 138 139 the origin of mutation in formalin-fixation paraffin-embedding (FFPE) samples was applied (R-package EXCERNO v0.1.0)<sup>28</sup>. Variants annotated with an FFPE-like signature were 140 141 removed. Potential germline variants in the data were removed using GATKs 1000g Panel of Normals. The top 20 frequently mutated genes (FLAGS)<sup>29</sup> were removed from further 142 143 analysis and the remaining somatic variants were filtered as follows: minimum coverage of 144 50, minimum alternative allele coverage of 5, minimum variant allele frequency of 10%, and 145 only variants with a frequency < 0.1% in 1000 genomes, GNOMAD, or ExAC were 146 considered for subsequent downstream analysis; variants were required to have a COSMIC or 147 dbSNP ID. High-impact variants (CADD score > 20) in candidate genes (see below) were 148 filtered as such that minimum coverage of 10, minimum alternative coverage of 4, and 149 minimum variant allele frequency of 10% was required. Candidate genes were defined as follows: (a) listed as tumor suppressor or oncogene according to Vogelstein et al.  $^{30}$ , (b) genes 150 151 from the Lymphgen algorithm, (c) DLBCL genes described by Chapuy et al., (d) MHC genes according to Harmonizome  $(v3.0)^{31-33}$ . A brief graphical representation of the bioinformatics 152 153 workflow for WES data processing is provided in Supplementary Figure S1.

154

#### **155** Detection of Somatic Copy Number Alterations

Somatic copy number alterations were detected using OncoScan CNV assays (ThermoFisher).
Raw data (CEL files) were processed using the EACON package (v0.3.6-2) with SEQUENZA
as segmentation algorithm <sup>34</sup>. L2R files in CBS format were used as input for GISTIC
(v2.0.22) to identify regions significantly amplified or deleted across all samples (confidence
level 0.90, focal length cutoff 0.5, q-value threshold 0.1) <sup>34, 35</sup>.
For details on transcriptome data quantification, fusion detection, statistical analysis, and

163 pseudonymization, please see **Supplementary Materials and Methods**.

164

165 **Results** 

#### 166 Clinicopathological Characteristics and Cell-of-Origin in PR-DLBCL

We collected 34 PR-DLBCL samples from 30 patients with sufficient FFPE tissue samples for in-depth molecular characterization (**Figure 1A**). The median age of the study group was 66.5 years, 13 patients were female and 17 were male. No iatrogenic immunosuppression, immunodeficiency, and history or current presence of other lymphomas were reported in any of the patients. In particular, only patients without suspicion of concurrent lymphoma manifestations were eligible for the study. This is mirrored in the exceptionally high frequency of cases that underwent surgical resection of the kidney (22/34 cases; 65%).

174 Baseline clinicopathological data are summarized in **Supplementary Table 1**.

175 Structural variants in *BCL2*, *BCL6*, and *MYC* were assessed successfully in 19, 18, and 17 176 patients by FISH break-apart probes. In cases without sufficient tissue for FISH but with 177 RNA-seq data, we screened for high-confidence *BCL2/BCL6/MYC* fusions (**Figure 1 B**). 178 Here, we observed aberrations in five (26 %), two (11 %), and three (18%) cases respectively, 179 indicative of a slightly elevated frequency of these aberrations in comparison to DLBCL 180 (NOS) of other primary manifestations. In addition, we observed two cases with ETV6-Ig

181 fusions, previously described in PCNSL another case of an ETV6:PAX5 fusion respectively, 182 previously described to lead to similar ETV6 activation in B-cell precursor acute lymphoblastic leukemia <sup>36, 37</sup>. Manually curated oncogenic fusions derived from RNA-seq 183 184 data are summarized in **Supplementary Table 2**. By immunohistochemistry according to the 185 Hans et al. algorithm in all samples with sufficient tissue available after DNA/RNA 186 extraction, we observed the majority of cases to be of non-GCB type (18/30; 60%), whereas 187 only a minor subset was of GCB type (11/30; 37%), and one case could not be classified due to insufficient immunoreactivity <sup>38</sup>. Only one case was EBV-associated (>50% positive tumor 188 189 cells by EBER-ISH). To further unravel the cell of origin, we performed RNA-seq on samples 190 from 30 patients and applied the approach proposed by Wright et al. and found 15/30 cases 191 (50%) to be of ABC-subtype. In comparison, 9/30 (30%) were GCB-DLBCL and six remaining cases (20%) remained unclassifiable <sup>31, 39</sup> (Figure 1 C). 192

193

#### 194 The mutational landscape of PR-DLBCL

195 To elucidate the mutational landscape of PR-DLBCL and to screen for mutational drivers of 196 the subgroup's peculiar tropism, we performed WES on FFPE tissue samples from 34 patients

**197** (**Figure 1 D**).

198 Adhering to stringent variant filtering, outlined above, oncogenic mutations were identified in 199 all PR-DLBCL cases. In total 3,178 presumably deleterious mutations, affecting 1,388 genes 200 were observed. Additionally, 25,457 somatic copy number aberrations (SCNAs) were 201 detected. SNVs and indels comprised 11% of these mutations, of which 2,673 were missense 202 (84%), 333 nonsense (10%) and 70 indel mutations (2%). Mutations affecting splice sites 203 represented 3% of estimated somatic mutations and one of the observed mutations was a non-204 stop mutation (Supplementary Table 3). At an intermediate-low median tumor mutational 205 burden (TMB) of 2.45 mutations/Mb (range 0.18 - 5.76), we observed no cases of 206 microsatellite instability as could be expected in aggressive B-cell lymphomas. Variants per

207 variant class as well as variants per sample including information on variant subtypes are

### 208 provided in **Supplementary Figure S2**.

209 The most commonly mutated genes included chromatin-remodeling genes CREBBP and 210 KMT2D both in 56% of cases with > 20% nonsense mutations, followed by NOTCH 211 signaling-associated genes SPEN and NOTCH2 (both 50%) with nonsense mutations in 47% 212 and 18% respectively. Overall, we observed an enrichment in IL6/JAK/STAT3 signaling 213 mutations including STAT3, PIM1, and MYD88. While STAT3 mutations were distributed 214 throughout the entire gene, we observed mutational impairment of pre-described hotspots in 215 MYD88 and PIM1 (all restricted to the kinase domain) (Figure 2). Other biological processes 216 targeted by deleterious mutations in PR-DLBCL included the epigenetic regulation of gene 217 expression (SF3B1, KMT2D, and EZH2), as well as B-cell receptor and RTK-RAS signaling 218 (CARD11, PRDM1, and BRAF). The distribution of mutation onto the candidate driver genes 219 referenced above is displayed in Figure 2. In a more global approach, we assessed the 220 impairment of key biological processes through an enrichment analysis of mutations against 221 previously described oncogenetic gene sets and against the IL6/JAK/STAT3 signaling 222 pathway (**Figure 3**)<sup>40</sup>. Hereby we uncovered a relatively wide distribution within a given set 223 (Figure 3A). Intriguingly, the most commonly affected gene sets included NOTCH, RTK-224 RAS, and IL6/JAK/STAT signaling at 97%, 94%, and 91%, respectively (Figure 3 B, C). 225 Beyond this, we observed mutational impairment of PI3K signaling in 79% of cases, 226 suggesting a significant role in PR-DLBCL pathogenesis. Correlating information on cell of 227 origin and mutational patterns, we observed a statistically significant enrichment in mutations 228 affecting TNFAIP3 and PIM1 among non-GCB cases. BCL2 rearranged cases showed 229 significantly more DNMT1 and SMARCA4 mutations (Supplementary Figure S3). We 230 additionally screened for recurrent mutations in canonical tumor suppressor genes (TSGs) and 231 found deleterious mutations in 33/34 (97%) cases. Among the most common targets, in 232 addition to *CREBBP* and *KMT2D*, we observed mutations in *TP53* in 15% of cases.

233

#### 234 Genome-wide analysis of somatic copy-number variations in primary renal DLBCL

235 To unravel the genome-wide landscape of SCNA in PR-DLBCL, we analyzed 29 samples 236 successfully on the Illumina OncoScan array and subsequently employed GISTIC (v2.0.22) to 237 identify regions significantly amplified or deleted across all samples. Arguably the most 238 striking observation was a broad arm-level deletion spanning a large region on chromosome 6 239 in 48% of evaluable cases (Figure 4A). Candidate genes, previously implicated in lymphoma 240 pathogenesis located in this vast region included PRDM1, NFKBIE, HLA-A, HLA-B, and 241 ARID1B. Beyond this aberration, the genome-wide CNV landscape of PR-DLBCL is 242 dominated by CNVs affecting 3p12.1 and leading to copy number losses of VHL, SETD2, 243 and others (17%), 9p21.3 encompassing the region encoding for TSG CDKN2A (38%), as 244 well as the *NOTCH1* region at 9q34.3 (28%). Focal amplifications were observed at 1q23.1, 245 3p12.3, 3q29, and 22q11.23. Candidate genes among significant deletions and amplifications 246 are provided in **Supplementary Table 4** and **Figure 4B**. To assess the characteristics of PR-247 DLBCL in contrast to transcriptionally defined subtypes of DLBCL (ABC/GCB) and primary 248 CNS lymphoma (PCNSL) as well as primary testicular large B-cell lymphoma (PTLBL) 249 together representing the subgroup of primary large B-cell lymphomas of immune-privileged 250 sites. We conducted a comparative analysis drawing CNV data from two previously published large-scale genome-wide studies (Figure 4 C)<sup>41, 42</sup>. Apart from a focal 3q29 amplification, 251 252 none of the previously reported copy number gains were observed at a significant level in our 253 cohort. At the same time and of particular interest, we observed strong similarities between 254 PR-DLBCL, PCNSL, and PTLBL regarding deletions at 6p21.33, 6q21, and 6q23.3. 255 Candidate gene deletions previously implicated in post-germinal differentiation and strong 256 CNS tropism located at these loci include HLA-B and PRDM1. Moreover, we identified the 257 above-mentioned CDKN2A deletions in PR-DLBCL at a frequency more similar to 258 PCNSL/PTLBL than an all-comer DLBCL cohort. Additionally, we observed a significant

259 impact of SCNAs on gene-expression profiles which is shown exemplarily for TSGs260 (Supplementary Figure S4).

261

#### 262 Molecular clusters in primary renal DLBCL

263 Building on our observations from WES, CNV analysis, RNA-seq, alongside structural 264 variants identified by FISH for BCL2, BCL6, and MYC, we performed an integrative analysis 265 on our entire cohort of PR-DLBCL samples to achieve an allocation to the previously defined 266 molecular clusters (A53, N1, BN2, EZB, and MCD) based on the probabilistic LymphGen 2.0 classifier <sup>31</sup>. Molecular data for an integrative analysis of sufficient sensitivity and specificity 267 268 was available in 30 cases. Unlike previous observations in PCNSL/PTLBL, only one case 269 resembled MCD-DLBCL. The most common molecular subtypes were ST2 (eight cases, 270 27%) and EZB (five cases, 17%). Of note, no double- or triple-hit lymphomas including 271 MYC+ EZB cases were observed. Only two cases were BN2-DLBCL (7%). While a 272 significant overlap between signatures with compound-cluster allocation was observed in 273 eight cases, six cases were found to exhibit a constellation of findings leading to a 274 classification as "other" (Figure 1 D and Supplementary Table 5).

275

#### 276 Immune-escape mechanisms in primary renal DLBCL as a driver of tropism

277 Following the characterization of the mutational profiles and molecular clusters that displayed 278 the significant heterogeneity outlined above, we sought to understand the underlying 279 mechanism behind the exceptional renal tropism in our present cohort. Building on our 280 observation of a significant overlap between PR-DLBCL, PCNSL, and PTLBL, in particular 281 regarding copy number losses affecting HLA-B as a hallmark gene of MHC Class I, we 282 sought to assess the extent to which the clinical behavior of PR-DLBCL might be explained 283 by immune escape strategies. Integrating all available datasets, we identified deleterious 284 MHC Class I lesions in 72% of cases, including HLA-A and HLA-B deletions in 48% and

deleterious B2M mutations in 21% of evaluable patients (**Figure 5A, B**). An additional fraction of 33% of patients exhibited deleterious aberrations within the MHC class II machinery and 60% of patients additionally exhibited molecular hits in immediate interaction partners of MHC class I or II required for adequate immune response including del 19p13.3 and mutations affecting CD70, CIITA, and CD58 (**Figure 5A, C**).

290 Having identified the large-scale 6p25.2-q27 deletion outlined above as a potential hallmark 291 of aggressive B-cell lymphomas with renal tropism, we went on to assess the transcriptional 292 profile of cases carrying said aberration and observed a significantly elevated expression of 293 several candidate genes (Figure 5D and Supplementary Table 6) including CXCL10 as well 294 as strong enrichment for interferon alpha and gamma response, MYC targets, JAK/STAT 295 signaling, and others (Figure 5E and Supplementary Table 7). In particular, we found 296 downstream NFkB activation via TNFalpha signaling. In addition, several metabolic 297 processes including glycolysis, fatty acid metabolism, and oxidative phosphorylation appear 298 to be particularly engaged compared to non-MHC-class I-deleted cases.

299 Subsequent analysis of our cohort deconvoluting cell states and their assembly into 300 communities of co-association patterns in the form of lymphoma ecotypes (LE) employing 301 the lymphoma EcoTyper revealed a relatively diverse composition of both the tumor as well as its microenvironment in PR-DLBCL<sup>43</sup>. Despite the limited number of cases, we observed 302 303 a trend towards enrichment in prognostically adverse ABC-DLBCL-associated lymphoma 304 ecotypes (LE) 2 and 4 dominated by B-cells, plasma cells, and dendritic cells as well as NK 305 cells, CD4 and CD8 positive T-cells alongside regulatory T-cells, respectively in del 6p25.2-306 q27 cases. Moreover, a trend towards enrichment of the T follicular helper cells dominated LE5 was observed in non-del 6p25.2-q27 cases <sup>43</sup>. The distribution of ecotypes on cases is 307 308 depicted in Figure 6 (Supplementary Table 8).

309

310 Discussion

311 Primary renal DLBCL poses a rare phenomenon associated with adverse clinical features and 312 outcomes, including a so far unexplained CNS tropism leading to significant mortality, 313 especially in relapsed and/or refractory cases <sup>6</sup>. This study was initiated to unravel the 314 molecular underpinnings of primary renal disease, to allow for an understanding as to why 315 and how the disease originates in an organ without a genuine lymphatic niche, and to explain 316 the clinically observed tendency of early CNS progression. To this end, we conducted an 317 integrative analysis employing WES, RNA-seq and array-based SCNV analysis on the largest 318 cohort of PR-DLBCL studied to date.

319 Hereby, we made the following noteworthy observations. First, we provide a detailed 320 molecular landscape of PR-DLBCL and observe a strong degree of heterogeneity in terms of molecular clusters according to the LymphGen algorithm <sup>31</sup>. Contrary to our initial 321 322 expectation, we observed a relatively low frequency of *MYD88* mutations. Therefore only one 323 case that was allocated to the characteristic MCD cluster, which is otherwise recurrently 324 observed in both primary and secondary CNS lymphoma as well as testicular lymphoma. 325 Tropism for immune-privileged sites appears to be driven by immune escape strategies, which 326 may be augmented by activating mutations in the B-cell receptor signaling cascade <sup>31, 32, 44, 45</sup>. 327 Beyond this, we saw a high frequency of SPEN mutations previously described to be 328 associated with early progression and inferior outcome in an all-comer DLBCL cohort <sup>46</sup>. 329 Significant deregulation of TSGs was further validated via an integrative analysis of SCNAs 330 and transcriptional abundance. Among the genes most commonly affected by mutations 331 within our cohort, potentially targetable vulnerabilities included recurrent mutations in genes 332 like EZH2 for which clinically active inhibitors have been described previously, including 333 combinations with BCL2 inhibitors in patients with co-occurrence of EZH2 and BCL2 334 aberrations, which we observed in our cohort as well. At the same time, recurrent CARD11 335 mutations, downstream of Bruton's tyrosine kinase (BTK) may render therapeutic 336 approaches, employing BTK inhibitors inefficient in a clinically meaningful subset of patients

<sup>47-49</sup>. Given the peculiar tropism of PR-DLBCL, the abundance of *STAT3* mutations appears 337 338 striking. In addition to the known cooperative interplay between STAT3 and the NFkB 339 signaling cascade in post-germinal DLBCL, this may further be explained as a selection 340 advantage throughout clonal evolution. In keeping with previous observations that linked 341 STAT3 mutations and its elevated activity to the modulation of the abundance and function of 342 regulatory T cells in the TME of solid cancers, this suggests a therapeutical perspective 343 involving STAT3 inhibition which might be able to target the TME and its permissive impact on the immunological niche in PR-DLBCL <sup>50, 51</sup>. An additional candidate driver for early 344 345 progression and CNS dissemination is the relatively high rate of MYC aberrations in more than 17% of evaluable cases  $5^{2}$ . 346

347 Second, we describe a profile of SCNA and mutations leading to significant impairment of 348 MHC class I/II families and its immediately associated genes in approx. 95% of cases in the cohort, which significantly exceeds observations in all-comer DLBCL cohorts <sup>32, 53</sup>. From 349 350 these observations, we deduce a strong overlap between PR-DLBCL and large B-cell 351 lymphomas of immune-privileged sites (IP-LBCL) regarding SCNAs. At the same time, PR-352 DLBCL apparently lacks the characteristic mutational profile resulting in tonic B-cell receptor signaling usually associated with this newly described entity <sup>1, 54</sup>. It is tempting to 353 354 speculate on a theory of a first and second hit in the central nervous dissemination of PR-355 DLBCL acquiring the typical driver mutations in a second step, following the initial presence of strong immune-escape mechanisms <sup>55</sup>. To investigate this in future studies, paired analyses 356 357 of renal and CNS tumors will be required. Deleterious aberrations in MHC class I 358 components and related genes constitute well-documented phenomena in DLBCL. However, 359 the frequency at which this is observed in the present study, extending to highly recurrent alterations of MHC class II genes poses a significant enrichment <sup>32</sup>. Moreover, this aligns 360 361 with previous observations in primary CNS lymphoma and testicular lymphoma regarding 362 deletions of the HLA and CDKN2A loci and extends well beyond previous reports in ABC-

363 DLBCL by both immunohistochemistry and gene expression profiling <sup>41</sup>. Further in keeping 364 with pathogenetically similar trajectories between PR-DLBCL and other IP-LBCL, we 365 observed 10% of cases harboring *ETV6* rearrangements previously reported as recurrent, 366 oncogenic structural variants and drivers of a post-germinal phenotype in PCNSL <sup>36</sup>.

367 Third, we describe a characteristic transcriptional profile in cases harboring MHC class I 368 SCNAs as a newly described hallmark of primary renal DLBCL. It is predominantly 369 characterized by a strong enrichment for interferon alpha and gamma responses, MYC targets, 370 and JAK/STAT signaling and downstream NFkB activation via TNF-alpha signaling. All of 371 these mechanisms are known drivers, especially of ABC-DLBCL. TNF signaling was 372 recently shown to aberrantly remodel the fibroblastic reticular cell (FRC) network and contribute to a tolerogenic TME hindering therapeutic efficacy of immune-based therapies <sup>51,</sup> 373 374  $^{56}$ . Further, several metabolic processes including glycolysis, fatty acid metabolism, and 375 oxidative phosphorylation appear particularly engaged. This could be particularly interesting 376 in future targeted therapeutical approaches exploiting this dependence, as recently described 377 <sup>57</sup>. In addition, we observed a trend towards enrichment of LE2- and LE4-high states in our 378 predominantly ABC-like group of MHC class I deleted tumors, in keeping with previous 379 observations from all-comer DLBCL cohorts where these lymphoma ecotypes were associated with inferior clinical outcomes <sup>43</sup>. The trend towards more LE5-high tumors in the 380 381 non-MHC class I deleted cases with its underlying cell states being more prevalent in healthy 382 lymphoid tissues integrates seamlessly with this notion.

The study presents several limitations, inherent to the retrospective design. Despite this being the largest cohort of PR-DLBCL to date the sample size remains limited and samples for the study were collected over more than two decades. This results in significant heterogeneity in terms of first- and later-line treatment approaches and limited follow-up information. These factors prohibit a meaningful integrative analysis of molecular findings and clinical endpoints. In addition, there is a potential for cases with occult non-renal primary

manifestations, which may have been missed by diagnosing physicians. However, considering
that secondary renal manifestations typically occur in advanced-stage disease, the likelihood
of a significant fraction of patients harboring secondary renal manifestations is relatively low.
In summary, we present the largest molecular study on PR-DLBCL to date, untangle the
genomic and transcriptional heterogeneity of the disease, and uncover evidence of significant
pathogenetic overlap between PR-DLBCL and IP-LBCL. Our observations may inform future
risk-adapted therapeutic approaches.

# 397 Declarations

### 398 Ethics approval and consent to participate

This retrospective study was approved by the ethics committee of the University of Lübeck (reference-no 18-356) and conducted in accordance with the declaration of Helsinki. Patients have provided written informed consent regarding routine diagnostic and academic assessment, including genomic studies of their biopsy specimens alongside the transfer of their clinical data.

404

405

#### 406 Availability of data and material

407 Raw fastq files have been deposited in the European genome-phenome archive (EGA) under

408 the accession number EGA5000000386. OncoScan Array data has been deposited in Gene

409 Expression Omnibus (GEO) under accession number GSE270422.

410

# 411 Funding

412 This work was supported by generous funding by the Wilhelm Sander-Stiftung through a

413 project grant (NG; Grant-Nr.: 2021.150.1). HB and AK acknowledge support from the BMBF

414 project OUTLIVE-CRC (FKZ 01KD2103A).

415

### 416 Author contributions

- 417 Study concept: NG, ACF, HM
- 418 Data collection: NG, AK, VvK, PL, MK, HW, VB, SS, KK, HM, SS, KS, AA, ACF
- 419 Data analysis and creation of figures and tables: AK, NG, ACF, HB, NvB,
- 420 Initial Draft of manuscript: NG.
- 421 Critical revision and approval of final version: all authors.

422

### 423 Acknowledgements

- 424 The authors would like to thank Tanja Oeltermann for her skilled technical assistance. AK
- 425 and HB acknowledge computational support from the OMICS compute cluster at the
- 426 University of Lübeck.

### **References**

428	1.	Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al.	
429	The 5th edition of the World Health Organization Classification of Haematolymphoid		
430	Tumou	urs: Lymphoid Neoplasms. <i>Leukemia</i> 2022 Jul; <b>36</b> (7): 1720-1748.	
431			
432	2.	Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS	
433	Interna	ational Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse	
434	Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol 2016 Sep 10; 34(26): 3150-		
435	3156.		
436			
437	3.	Hu R, Zhang R, Miao M, Zhu K, Yang W, Liu Z. Central nervous system involvement	
438	of prin	nary renal lymphoma with diffuse large B-cell type lymphoma. Am J Case Rep 2013;	
439	<b>14:</b> 29	2-294.	
440			
441	4.	Gibson TE. Lymphosarcoma of the kidney. J Urol 1948 Dec; 60(6): 838-854.	
442			
443	5.	Kandel LB, McCullough DL, Harrison LH, Woodruff RD, Ahl ET, Jr., Munitz HA.	
444	Primar	ry renal lymphoma. Does it exist? <i>Cancer</i> 1987 Aug 1; <b>60</b> (3): 386-391.	
445			
446	6.	Okuno SH, Hoyer JD, Ristow K, Witzig TE. Primary renal non-Hodgkin's lymphoma.	
447	An un	usual extranodal site. Cancer 1995 May 1; 75(9): 2258-2261.	
448			
449	7.	Taneja A, Kumar V, Chandra AB. Primary renal lymphoma: A population-based	
450	analys	is using the SEER program (1973-2015). Eur J Haematol 2020 May; <b>104</b> (5): 390-399.	
451			
452	8.	Chen J, Peng J, Zheng Y, Li S, Yang P, Wu X, et al. Primary renal lymphoma: a	
453	popula	tion-based study in the United States, 1980-2013. Sci Rep 2019 Oct 22; 9(1): 15125.	
454			
455	9.	Chen X, Hu D, Fang L, Chen Y, Che X, Tao J, et al. Primary renal lymphoma: A case	
456	report	and literature review. Oncol Lett 2016 Nov; <b>12</b> (5): 4001-4008.	
457			
458	10.	Nicolau C, Sala E, Kumar A, Goldman DA, Schoder H, Hricak H, et al. Renal Masses	
459	Detect	ed on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating	

460	Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement. AJR Am J		
461	Roentgenol 2017 Apr; 208(4): 849-853.		
462			
463	11. Garcia M, Konoplev S, Morosan C, Abruzzo LV, Bueso-Ramos CE, Medeiros LJ.		
464	MALT lymphoma involving the kidney: a report of 10 cases and review of the literature. Am		
465	J Clin Pathol 2007 Sep; 128(3): 464-473.		
466			
467	12. Wen S, Liu T, Zhang H, Zhou X, Jin H, Sun M, et al. Whole-Exome Sequencing		
468	Reveals New Potential Mutations Genes for Primary Mucosa-Associated Lymphoid Tissue		
469	Lymphoma Arising From the Kidney. Front Oncol 2020; 10: 609839.		
470			
471	13. Künstner A, Schwarting J, Witte HM, Bernard V, Stölting S, Kusch K, et al.		
472	Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of		
473	blastic plasmacytoid dendritic cell neoplasm. Blood Cancer Journal 2022 2022/07/04; 12(7):		
474	101.		
475			
476	14. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, e		
477	al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from		
478	the Clinical Advisory Committee. <i>Blood</i> 2022 Sep 15; <b>140</b> (11): 1229-1253.		
479			
480	15. Witte HM, Kunstner A, Hertel N, Bernd HW, Bernard V, Stolting S, et al. Integrative		
481	genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key		
482	regulatory pathways. Blood Adv 2021 Oct 29.		
483			
484	16. Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core		
485	framework for community-curated bioinformatics pipelines. Nat Biotechnol 2020 Mar; 38(3)		
486	276-278.		
487			
488	17. Hanssen F, Garcia MU, Folkersen L, Pedersen AS, Lescai F, Jodoin S, et al. Scalable		
489	and efficient DNA sequencing analysis on different compute infrastructures aiding variant		
490	discovery. NAR Genom Bioinform 2024 Jun; 6(2): lqae031.		
491			
492	18. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.		
493	Bioinformatics 2018 Sep 1; 34(17): i884-i890.		

494			
495	19.	Vasimuddin M, Misra S, Li H, Aluru S. Efficient Architecture-Aware Acceleration of	
496	BWA	A-MEM for Multicore Systems. 2019 IEEE International Parallel and Distributed	
497	Proc	essing Symposium (IPDPS) 2019: 314-324.	
498			
499	20.	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The	
500	Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA		
501	seque	encing data. Genome Res 2010 Sep; 20(9): 1297-1303.	
502			
503	21.	Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP:	
504	the N	CBI database of genetic variation. Nucleic Acids Res 2001 Jan 1; 29(1): 308-311.	
505			
506	22.	Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al.	
507	Sens	tive detection of somatic point mutations in impure and heterogeneous cancer samples.	
508	Nat I	<i>Biotechnol</i> 2013 Mar; <b>31</b> (3): 213-219.	
509			
510	23.	Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The	
511	mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020		
512	May;	<b>581</b> (7809): 434-443.	
513			
514	24.	McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl	
515	Varia	ant Effect Predictor. Genome Biol 2016 Jun 6; 17(1): 122.	
516			
517	25.	Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the	
518	deleteriousness of variants throughout the human genome. Nucleic Acids Res 2019 Jan 8;		
519	<b>47</b> (D1) <b>:</b> D886-D894.		
520			
521	26.	Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic	
522	muta	tional constraint map using variation in 76,156 human genomes. Nature 2024 Jan;	
523	625(	7993): 92-100.	
524			
525	27.	Diossy M, Sztupinszki Z, Krzystanek M, Borcsok J, Eklund AC, Csabai I, et al. Strand	
526	Orier	ntation Bias Detector to determine the probability of FFPE sequencing artifacts. Brief	
527	<i>Bioinform</i> 2021 Nov 5; <b>22</b> (6).		

528			
529	28.	Mitchell A, Ruiz M, Yang S, Wang C, Davila JI. Excerno: Using Mutational	
530	Signatures in Sequencing Data to Filter False Variants Caused by Clinical Archival. J Comput		
531	Biol 2	2023 Apr; <b>30</b> (4): 366-375.	
532			
533	29.	Shyr C, Tarailo-Graovac M, Gottlieb M, Lee JJ, van Karnebeek C, Wasserman WW.	
534	FLAG	GS, frequently mutated genes in public exomes. BMC Med Genomics 2014 Dec 3; 7: 64.	
535			
536	30.	Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW.	
537	Cance	er genome landscapes. Science 2013 Mar 29; <b>339</b> (6127): 1546-1558.	
538			
539	31.	Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A	
540	Proba	bilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma	
541	with '	Therapeutic Implications. <i>Cancer Cell</i> 2020 Apr 13; <b>37</b> (4): 551-568 e514.	
542			
543	32.	Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular	
544	subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic		
545	mech	anisms and outcomes. Nat Med 2018 May; 24(5): 679-690.	
546			
547	33.	Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott	
548	MG,	et al. The harmonizome: a collection of processed datasets gathered to serve and mine	
549	know	ledge about genes and proteins. Database (Oxford) 2016; 2016.	
550			
551	34.	Favero F, Joshi T, Marquard AM, Birkbak NJ, Krzystanek M, Li Q, et al. Sequenza:	
552	allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol		
553	2015	Jan; <b>26</b> (1): 64-70.	
554			
555	35.	Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G.	
556	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-		
557	numb	er alteration in human cancers. Genome Biol 2011; 12(4): R41.	
558			
559	36.	Bruno A, Labreche K, Daniau M, Boisselier B, Gauchotte G, Royer-Perron L, et al.	
560	Identi	fication of novel recurrent ETV6-IgH fusions in primary central nervous system	
561	lymphoma. Neuro Oncol 2018 Jul 5; <b>20</b> (8): 1092-1100.		

562			
563	37.	Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, et al. Molecular role	
564	of the	PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia. <i>EMBO J</i>	
565	2017	Mar 15; <b>36</b> (6): 718-735.	
566			
567	38.	Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al.	
568	Confi	rmation of the molecular classification of diffuse large B-cell lymphoma by	
569	immu	nohistochemistry using a tissue microarray. Blood 2004 Jan 1; 103(1): 275-282.	
570			
571	39.	Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-	
572	based	method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.	
573	Proc	Natl Acad Sci U S A 2003 Aug 19; 100(17): 9991-9996.	
574			
575	40.	Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic	
576	Signa	ling Pathways in The Cancer Genome Atlas. Cell 2018 Apr 5; 173(2): 321-337 e310.	
577			
578	41.	Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable	
579	genet	ic features of primary testicular and primary central nervous system lymphomas. Blood	
580	2016	Feb 18; <b>127</b> (7): 869-881.	
581			
582	42.	Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, et al. Integrative	
583	analy	sis reveals an outcome-associated and targetable pattern of p53 and cell cycle	
584	dereg	ulation in diffuse large B cell lymphoma. Cancer Cell 2012 Sep 11; 22(3): 359-372.	
585			
586	43.	Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The	
587	landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell		
588	2021	Oct 11; <b>39</b> (10): 1422-1437 e1410.	
589			
590	44.	Wright GW, Wilson WH, Staudt LM. Genetics of Diffuse Large B-Cell Lymphoma. N	
591	Engl	<i>J Med</i> 2018 Aug 2; <b>379</b> (5): 493-494.	
592			
593	45.	Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, et al. The genomic and	
594	transo	criptional landscape of primary central nervous system lymphoma. Nat Commun 2022	
595	May	10; <b>13</b> (1): 2558.	

596			
597	46.	Ren W, Wan H, Own SA, Berglund M, Wang X, Yang M, et al. Genetic and	
598	transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within		
599	two y	ears of diagnosis. Leukemia 2024 Mar; 38(3): 610-620.	
600			
601	47.	Caeser R, Walker I, Gao J, Shah N, Rasso-Barnett L, Anand S, et al. Acquired	
602	CARI	D11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma. JCO	
603	Preci	s Oncol 2021; <b>5:</b> 145-152.	
604			
605	48.	Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined	
606	EZH2	and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.	
607	<i>Blood Adv</i> 2020 Oct 27; <b>4</b> (20): 5226-5231.		
608			
609	49.	Morschhauser F, Salles G, Batlevi CL, Tilly H, Chaidos A, Phillips T, et al. Taking	
610	the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood Rev 2022		
611	Nov; <b>56:</b> 100988.		
612			
613	50.	Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, et al. STAT3	
614	Modu	lation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck	
615	Cance	er. J Natl Cancer Inst 2019 Dec 1; <b>111</b> (12): 1339-1349.	
616			
617	51.	Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative	
618	signaling through the signal transducer and activator of transcription 3 and nuclear factor-		
619	kappaB pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008 Apr 1; 111(7):		
620	3701-3713.		
621			
622	52.	Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, et al.	
623	Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large		
624	B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. J Clin		
625	Onco	l 2019 Dec 10; <b>37</b> (35): 3359-3368.	
626			
627	53.	Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al.	
628	Genet	tics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 2018 Apr 12;	
629	<b>378</b> (1	5): 1396-1407.	

631	54.	Roschewski M, Phelan JD, Jaffe ES. Primary Large B-cell Lymphomas of Immune-	
632	Privil	eged Sites. Blood 2024 Apr 18.	
633			
634	55.	Watanabe J, Natsumeda M, Okada M, Kobayashi D, Kanemaru Y, Tsukamoto Y, et	
635	al. High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With		
636	CNS Lymphomas. JCO Precis Oncol 2019 Dec; 3: 1-13.		
637			
638	56.	Apollonio B, Spada F, Petrov N, Cozzetto D, Papazoglou D, Jarvis P, et al. Tumor-	
639	activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. $J$		
640	Clin I	Invest 2023 Jul 3; <b>133</b> (13).	
641			
642	57.	Noble RA, Thomas H, Zhao Y, Herendi L, Howarth R, Dragoni I, et al. Simultaneous	
643	targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse		
644	large	B-cell lymphoma. Br J Cancer 2022 Sep; <b>127</b> (5): 937-947.	
645			
646			

647

### 648 Figure Legends:

649

650 Figure 1. Molecular landscape of PR- DLBCL. A Venn diagram depicting the number of samples 651 for which WES (n = 34), RNA-seq (n = 30), and OncoScan arrays (n = 29) were successfully 652 conducted. **B** Fusion identified by RNA-sequencing in PR-DLBCL samples (beyond 653 MYC/BCL2/BCL6 rearrangements identified in cases studied by FISH) displayed by their genomic 654 location. C Sankey plot illustrating the distribution of cases of PR-DLBCL into the categories 655 GCB/non-GCB by immunohistochemistry (IHC) according to the algorithm proposed by Hans et al.<sup>38</sup> 656 as well as by Cell-of-origin (CoO) classified according to gene-expression profiling <sup>39</sup> derived from 657 RNA-seq and lastly according to molecular clusters drawn from the LymphGen algorithm, integrating data from WES, RNA-seq, Oncoscans, and FISH (BCL2/BCL6/MYC)<sup>31</sup>, depicting the significant 658 659 degree of molecular heterogeneity. D Oncoplot displaying putative driver genes and the number of 660 samples harboring mutations in a given gene (right bar). Mutation types are color-coded, and 661 covariates, including sex, CoO, FISH results for BCL2/BCL6/MYC, and type of biopsy (punch/needle 662 core vs. open resection/nephrectomy) are shown below for each sample.

663

Figure 2. Recurrently mutated putative drivers of PR-DLBCL. Lollipop plots illustrating types and location of mutations, grouped by affected signaling pathway and/or biological function. Functional domains are depicted as a frame of reference and the lollipops' height indicates the frequency with which a given mutation occurred in our cohort.

668

Figure 3. Functional implication of mutations in PR-DLBCL. A Fraction of a given pathway,
biological function, or gene set impaired by mutations is depicted as the number of affected genes vs.
the number of genes in a given set. B Distribution of mutational impairment of gene sets per sample,
including fraction of samples harboring one or more mutations in a given gene set.

673

674 Figure 4. Somatic copy-number aberrations in **PR-DLBCL** compared with other subtypes of

675 **DLBCL including IP-LBCL.** A Location of SCNAs along the genome and GISTIC G-scores (G =

Frequency × Amplitude; red bars denote gains and blue bars losses; gene names refer to affected oncogenes and tumor suppressor genes within identified regions). B Tumor suppressor genes affected by copy number losses. C Amplifications and deletions at recurrently affected loci in an all-comer cohort of DLBCL (first column), DLBCL of ABC- as well as GCB-subtype (second and third column) and IP-LBCL with primary CNS or primary testicular manifestation (column four and five) compared to primary renal DLBCL (column six).

682

683 Figure 5. Immune escape is the predominant molecular feature of PR-DLBCL. A Impairment of 684 the MHC class I and II apparatus as well as its immediate interaction partners by mutations and/or 685 SCNAs. B, C Lollipop plots illustrating types and location of mutations in B2M and CIITA as 686 recurrently mutated genes associated with immune escape in PR-DLBCL. Functional domains are 687 depicted as a frame of reference and the lollipops' height indicates the frequency with which a given 688 mutation occurred in our cohort. D Volcano plot illustrating results of a genome-wide screen for 689 significantly deregulated genes by the presence or absence of a large-scale deletion on chromosome 6 690 leading to strong MHC class I impairment as the most recurrent and striking feature in PR-DLBCL. 691 E Gene-set enrichment analysis depicting functional implications of deregulated gene expression 692 between cases with and without large-scale MHC class I deletions.

Figure 6. Deconvolution of PR- DLBCL transcriptomes employing the lymphoma EcoTyper. A Heatmap displaying the cell-type abundance as well as the predominant EcoType for a given PR-DLBCL sample. B Comparative analysis of lymphoma EcoType abundances according to the presence or absence of a large-scale deletion on chromosome 6 leading to strong MHC class I impairment as the most recurrent and striking feature in prDLBC, grouped by lymphoma EcoTypes.





19

D

# A NOTCH Signaling

# B IL6/JAK/STAT3 Signaling









